Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.Supporting the future of our business and the health and well-being of patients, people and communities around the world.We follow the science to our next breakthrough, leaving no stone unturned.Merck announced second-quarter worldwide sales of $10.9 billion – a decrease of 8% compared with the second quarter of 2019 – reflecting the negative impact of COVID-19. Excluding the impact from foreign exchange, sales declined 5%. Measles is an attractive vector because the measles vaccine has proven safe and effective for billions of children over the past 40 years. The scientific basis for Themis’ measles vector platform was developed at the world renowned Institut Pasteur in Paris and is now licensed to Themis.
[Illustrator: Alissa Eckert / U.S. Centers for Disease Control and Prevention]The partners will develop vaccine candidates based on Themis’ measles virus vector-based platform. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications. © 2018 Themis Bioscience GmbH Muthgasse 11/2, 1190 Vienna, office@themisbio.com, T +43 / 1 / 236 7151 We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Consortium to be led by the Institut Pasteur and will include Themis and the University of Pittsburgh. The vaccines are designed to deliver multiple selected antigens directly to macrophages and dendritic cells, thus triggering a specific immune response to the selected antigens . The scientific basis for Themis’ measles vector platform was developed at the world renowned Institut Pasteur in Paris and is now licensed to Themis. The vaccine delivers the selected antigens directly to macrophages and dendritic cells – the most potent and effective antigen-presenting cells, thereby triggering a specific immune response to the selected antigens.
If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. The partners will develop vaccine candidates based on Themis’ measles virus vector-based platform. As a company dedicated to saving and improving lives for more than 100 years, we have a special responsibility to help in the fight against COVID-19.
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. We are called MSD everywhere, except in the United States and Canada where we are known as Merck & Co Inc, Kenilworth, NJ USA Private Securities Litigation Reform Act of 1995. The Austrian biotech Themis -- specializing in vaccines for infectious and insect-borne diseases -- has jumped on the coronavirus vaccine bandwagon along with the Institut Pasteur and other international partners. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. As a replicating vector, the vaccine continuously expresses antigens even after immunization. Themis has also developed an efficient and robust manufacturing process for its product candidates. In March, Themis joined a consortium together with the Institut Pasteur and … The partners will develop vaccine candidates based on Themis’ measles virus vector-based platform. Themis … Copyright © 2020 Genetic Engineering & Biotechnology News. In 1943, our company tapped into the city’s workforce and resources, and moved into the neighborhood after buying a milk of magnesium manufacturing facility on East […]Receive company news, updates and other informationFind information about our quarterly reports, annual reports & proxy and SEC filingsSee stock quotes and charts on a monthly, quarterly or yearly basis Themis developed a broad pipeline of vaccine candidates and immune-modulatory therapies using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications. In March, Themis joined a consortium together with the Institut Pasteur and … Merck has been fully committed to developing an effective response to the COVID-19 pandemic since it was first […]The site sits at the center of an important biotechnology hub Decades before it became a hive of biotechnology activity, South San Francisco was a hotspot for manufacturing technologies. By engineering the virus to express different antigens, Themis …
By continuing, you will be directed to a site intended only for residents of the United States and Canada. CEPI to provide initial US$4.9 million for consortium to develop a COVID-19 vaccine candidate based on measles-vector technology. The platform enables the incorporation of large recombinant genes coding for selected antigens. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. This is the 2nd Zika vaccine program based on Themis’ measles vector platform to enter the clinic. The collaboration will be led by the Parisian Institut Pasteur, whose vaccine technology -- in this case modifying a measles virus vector to carry coronavirus antigens -- is licensed to Themis. Themis is developing a pipeline of vaccines based on a measles virus vector platform it licensed from Institut Pasteur. The potential vaccines will be developed using Themis’ measles virus vector-based platform, the vectors of which were exclusively licensed to Themis by the French Institut Pasteur. Private Securities Litigation Reform Act of 1995.